SVA
Sinovac Biotech Ltd
6.50$
+0.0%
vs. previous close
Closing price · As of: Sep 12, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q2 22 | Q3 22 | Q1 23 | Q2 23 | Q4 23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -118.5% | 4.5% | 12.2% | 146.9% | 146.9% | 82.8% | 74.6% | -66.7% | 127.5% | -75.4% | 412.3% | 47.4% | |
| 5.4% | 3.1% | 0.3% | 0.4% | 0.4% | 0.2% | 0.8% | 6.4% | 74.1% | 9.0% | -52.1% | 19.7% | |
| 4.9% | 1.4% | 6.9% | 0.2% | 0.2% | – | 0.0% | -72.7% | -3.4% | -0.6% | -105.7% | – | |
| -11.4% | 5.7% | 13.9% | 19.8% | – | – | – | – | – | – | – | – | |
| -74.4% | 2.9% | -11.7% | 93.5% | 93.5% | 5.0% | -1.0% | -141.9% | -104.9% | -17.5% | 0.0% | 90.3% | |
| 19.6% | 63.9% | 28.9% | 17.7% | 17.7% | 4.0% | 3.7% | 23.8% | 7.3% | 16.0% | 10.9% | 17.1% | |
| 166.7% | -91.5% | -26.3% | -46.5% | -46.5% | -29.8% | 3.0% | -295.7% | -816.5% | – | -1,945.1% | -63.4% | |
| – | – | – | – | – | 0.2% | 22.3% | 1.6% | 60.4% | 15.6% | 103.0% | – | |
| 0.0% | 0.0% | – | – | – | – | -5.0% | -45.7% | -72.7% | – | -94.4% | – | |
| 38.5% | 34.5% | 12.5% | 163.6% | – | – | – | – | – | – | – | – | |
| 43.2% | 40.6% | 20.0% | 165.4% | 165.4% | -0.3% | -22.2% | 1.0% | -119.1% | -49.2% | -571.2% | -95.2% | |
| 81.7% | -45.7% | 7.9% | 273.8% | 273.8% | 61.0% | 56.7% | -392.0% | 34.6% | 192.4% | -116.2% | -120.7% | |
| -138.1% | -59.4% | -16.7% | 129.2% | 129.2% | 78.7% | 71.0% | -90.5% | 120.2% | -91.4% | 401.4% | 30.3% |
Data as of: September 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.